Interleukin 34, from pathogenesis to clinical applications. (November 2017)

• Record Type: Journal Article
• Authors: Baghdadi, Muhammad; Endo, Hiraku; Tanaka, Yoshino; Wada, Haruka; Seino, Ken-ichiro
• Is Part Of: Cytokine. Volume 99(2017)
• Page Start: 139
• Page End: 147
• Publication Date: 2017-11
• Subjects: anti-CCP anti-cyclic citrullinated peptide antibody -- BMI body mass index -- CCL20 CC chemokine ligand 20 -- C/EBPβ CCAAT-enhancer-binding protein β -- CRP C-reactive protein -- CSF1R colony stimulating factor 1 receptor -- DAS28 disease activity score 28 -- DMARDs disease-modifying antirheumatic drug -- eGFR estimated glomerular filtration rate -- ERK extracellular-signal-regulated kinase -- ESR erythrocyte sedimentation rate -- HOMA-IR homeostasis model assessment for insulin resistance -- hsCRP high sensitivity C-reactive protein -- IL-1β interleukin-1β -- IL-6 interleukin-6 -- IL-17 interleukin-17 -- IL-23p19 interleukin-23p19 -- TJC tender joint count -- M-CSF macrophage colony-stimulating factor -- MMP-3 matrix metalloproteinase 3 -- NF-κB nuclear factor kappa B -- RANKL receptor activator of nuclear factor κB ligand -- RF rheumatoid factor -- RYGB Roux-en-Y bypass surgery -- SAT sc adipose tissue -- TAT total abdominal adipose tissue -- TGFβ1 transforming growth factor β1 -- TLR Toll-like receptor -- TNFα tumor necrosis factor-α -- VAT visceral adipose tissue; IL-34 -- Autoimmune diseases -- Inflammation -- Infection -- Cancer; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2017.08.020
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: IL-34 is expressed specifically in the skin and CNS under physiological conditions. IL-34 can be induced under various pathological conditions. IL-34 may serve as a diagnostic tool and novel biomarker of disease. IL-34 may serve as a promising therapeutic target in medicine. Abstract: Interleukin-34 (IL-34) is a hematopoietic cytokine that was described for the first time in 2008 as a second ligand of CSF1R in addition to M-CSF. IL-34 and M-CSF share no sequence homology, but have similar functions, affecting the biology of myeloid cell lineage. In contrast to M-CSF, IL-34 shows unique signaling and expression patterns. Physiologically, IL-34 expression is restricted to epidermis and CNS, acting as a regulator of Langerhans cells and microglia, respectively. However, IL-34 expression can be induced and regulated by NF-κB under pathological conditions. Importantly, growing evidence indicates a correlation between IL-34 and disease severity, chronicity and progression. In addition to its promising roles as a novel diagnostic and prognostic biomarker of disease, IL-34 may also serve as a powerful target for therapeutic intervention. Here, we review the current knowledge regarding the emerging roles of IL-34 in disease, and focus on the clinical applications of IL-34 in medicine.